These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28847181)

  • 1. Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2017 Oct; 18(14):1457-1465. PubMed ID: 28847181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical Management and Prevention of Motor Complications in Parkinson's Disease.
    Aradi SD; Hauser RA
    Neurotherapeutics; 2020 Oct; 17(4):1339-1365. PubMed ID: 32761324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
    Lang AE; Obeso JA
    Lancet Neurol; 2004 May; 3(5):309-16. PubMed ID: 15099546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor fluctuations in levodopa treatment: clinical pharmacology.
    Stocchi F; Bonamartini A; Vacca L; Ruggieri S
    Eur Neurol; 1996; 36 Suppl 1():38-42. PubMed ID: 8791020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.
    Leta V; Jenner P; Chaudhuri KR; Antonini A
    Expert Opin Drug Saf; 2019 Dec; 18(12):1203-1218. PubMed ID: 31619083
    [No Abstract]   [Full Text] [Related]  

  • 15. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
    Di Luca DG; Reyes NGD; Fox SH
    Drugs; 2022 Jul; 82(10):1027-1053. PubMed ID: 35841520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
    Jing XZ; Yuan XZ; Luo X; Zhang SY; Wang XP
    Curr Neuropharmacol; 2023; 21(8):1806-1826. PubMed ID: 35193486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
    Dézsi L; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
    Simms SL; Huettner DP; Kortagere S
    Neuropharmacology; 2016 Jan; 100():106-15. PubMed ID: 25896768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.